Trained scent dogs can identify presence of thyroid cancer in urine
the ONA take:
A trained scent dog is able to accurately identify presence of thyroid cancer in urine samples, a recent study presented at The Endocrine Society meeting in San Diego has found.
Donald Bodenner, MD, PhD, of the University of Arkansas for Medical Sciences and colleagues acquired urine samples from 34 patients before they went on to have a biopsy for suspicious thyroid nodules Previously, Bodenner’s co-author, Arny Ferrando, PhD, scent-trained a rescued German Shepherd-mix to recognize the smell of cancer in thyroid tissue, awarding the dog for identifying cancer samples while turning away from benign ones.
When presented with the samples, the dog was able to match final surgical pathology in 30 of the 34 patients, resulting in a true-positive rate of 86.7 percent as well as a true-negative rate of 89.5 percent.
The researchers plan to expand their program in collaboration with the Auburn University College of Veterinary Medicine in order to train two bomb-sniffing dogs to also detect thyroid cancer.
A trained scent dog is able to accurately identify presence of thyroid cancer in urine samples.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|